Phaseline

Companies › PainTEQ

PainTEQ: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LINQ system
Bone allograft implant for sacroiliac joint fusion
–Phase 4Sacroiliac Joint PainDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07558278LINQ systemPhase 4Sacroiliac Joint PainImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Lipogems International CellSeed R-Bio Wooshin Labottach Xentria

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.